期刊文献+

Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system 被引量:16

Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system
下载PDF
导出
摘要 AIM: To determine the role of Fas/Fas ligand (FasL) in the immune escape of colon cancer cells.METHODS: Immunohistochemistry was used to observe the expression of Fas and FasL in the tissues of colon cancer patients. In situ hybridization was used to detect the localization of FasL mRNA expression in cancer tissues.Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and CD45 staining were performed to detect the apoptosis of tumor-infiltrating lymphocytes (TILs). Co-culture assays of colon cancer cells (SW480) and Jurkat cells (Fas-sensitive cells) were performed to observe the counterattack of colon cancer cells to lymphocytes.RESULTS: Of 53 cases of colon carcinomas, 23 cases(43.4%) expressed Fas which was significantly lower as compared to the normal colonic mucosa (73.3%, P<0.01),and 45 cases (84.9%) of colon carcinomas expressed FasL, whereas only two cases (3.75%) in normal mucosa expressed FasL. FasL expression in the colon cancer cells was found to be associated with increased cell death of TILs. The apoptotic rate of TIL in the FasL-positive staining regions of tumor cells was significantly higher than that in the FasL-negative staining region (54.84±2.79% vs25.73±1.98%, P<0.01). The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on the SW480 cells. The apoptotic rates of Jurkat cells were found to be related with the amount of SW480 cells.CONCLUSION: Colon cancer cells can escape the immune surveillance and killing via decreasing Fas expression, and can counterattack the immune system via increasing FasL expression. Fas/FasL can serve as potential targets for effective antitumor therapy. AIM: To determine the role of Fas/Fas ligand (FasL) in the immune escape of colon cancer cells. METHODS: Immunohistochemistry was used to observe the expression of Fas and FasL in the tissues of colon cancer patients. In situ hybridization was used to detect the localization of FasL mRNA expression in cancer tissues. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and CD45 staining were performed to detect the apoptosis of tumor-infiltrating lymphocytes (TILs). Co-culture assays of colon cancer cells (SW480) and Jurkat cells (Fas-sensitive cells) were performed to observe the counterattack of colon cancer cells to lymphocytes. RESULTS: Of 53 cases of colon carcinomas, 23 cases (43.4%) expressed Fas which was significantly lower as compared to the normal colonic mucosa (73.3%, P〈0.01), and 45 cases (84.9%) of colon carcinomas expressed FasL, whereas only two cases (3.75%) in normal mucosa expressed FasL. FasL expression in the colon cancer cells was found to be associated with increased cell death of TIEs. The apoptotic rate of TIL in the FasL-positive staining regions of tumor cells was significantly higher than that in the FasL-negative staining region (54.84±2.79% vs 25.73±1.98%, P〈0.01). The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on the SW480 cells. The apoptotic rates of Jurkat cells were found to be related with the amount of SW480 cells. CONCLUSION: Colon cancer cells can escape the immune surveillance and killing via decreasing Fas expression, and can counterattack the immune system via increasing FasL expression. Fas/FasL can serve as potential targets for effective antitumor therapy.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第39期6125-6129,共5页 世界胃肠病学杂志(英文版)
关键词 结肠癌 直肠癌 肿瘤细胞 配合基 基因表达 病理机制 Colon neoplasm Fas system Immune counterattack
  • 相关文献

参考文献15

  • 1[1]Nagata S,Golstein P.The Fas death factor.Science 1995; 267:1449-1456
  • 2[2]Maher S,Toomey D,Condron C,Bouchier-Hayes D.Activation-induced cell death:the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.Immunol Cell Biol 2002; 80:131-137
  • 3[3]Perabo FG,Kamp S,Schmidt D,Lindner H,Steiner G,Mattes RH,Wirger A,Pegelow K,Albers P,Kohn EC,von Ruecker A,Mueller SC.Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.Br J Cancer 2001; 84:1330-1338
  • 4[4]Trauth BC,Klas C,Peters AM,Matzku S,Moiler P,Falk W,Debatin KM,Krammer PH.Monoclonal antibody-mediated tumor regression by induction of apoptosis.Science 1989; 245:301-305
  • 5[5]Yonehara S,Ishii A,Yonehara M.A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.J Exp Med 1989;169:1747-1756
  • 6[6]Krishnakumar S,Kandalam M,Mohan A,Iyer A,Venkatesan N,Biswas J,Shanmugam MP.Expression of Fas ligand in retinoblastoma.Cancer 2004; 101:1672-1676
  • 7[7]Abrams SI.Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.Front Biosci 2005;10:809-821
  • 8[8]Houston A,Bennett MW,O'Sullivan GC,Shanahan F,O'Connell J.Fas ligand mediates immune privilege and not inflammation in human colon cancer,irrespective of TGFbeta expression.Br J Cancer 2003; 89:1345-1351
  • 9[9]Okada K,Komuta K,Hashimoto S,Matsuzaki S,Kanematsu T,Koji T.Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.Clin Cancer Res2000; 6:3560-3564
  • 10[10]Ohta T,Elnemr A,Kitagawa H,Kayahara M,Takamura H,Fujimura T,Nishimura G,Shimizu K,Yi SQ,Miwa K.Fas ligand expression in human pancreatic cancer.Oncol Rep 2004;12:749-754

同被引文献57

引证文献16

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部